BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15014020)

  • 1. Detection and grading of soft tissue sarcomas of the extremities with (18)F-3'-fluoro-3'-deoxy-L-thymidine.
    Cobben DC; Elsinga PH; Suurmeijer AJ; Vaalburg W; Maas B; Jager PL; Hoekstra HJ
    Clin Cancer Res; 2004 Mar; 10(5):1685-90. PubMed ID: 15014020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
    Buck AK; Herrmann K; Büschenfelde CM; Juweid ME; Bischoff M; Glatting G; Weirich G; Möller P; Wester HJ; Scheidhauer K; Dechow T; Peschel C; Schwaiger M; Reske SN
    Clin Cancer Res; 2008 May; 14(10):2970-7. PubMed ID: 18445694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas.
    Been LB; Suurmeijer AJ; Elsinga PH; Jager PL; van Ginkel RJ; Hoekstra HJ
    J Nucl Med; 2007 Mar; 48(3):367-72. PubMed ID: 17332613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
    Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
    Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
    Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
    Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET.
    Benz MR; Dry SM; Eilber FC; Allen-Auerbach MS; Tap WD; Elashoff D; Phelps ME; Czernin J
    J Nucl Med; 2010 Aug; 51(8):1174-81. PubMed ID: 20660389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET.
    Cobben DC; van der Laan BF; Maas B; Vaalburg W; Suurmeijer AJ; Hoekstra HJ; Jager PL; Elsinga PH
    J Nucl Med; 2004 Feb; 45(2):226-31. PubMed ID: 14960640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
    Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
    J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas.
    Schwarzbach MH; Hinz U; Dimitrakopoulou-Strauss A; Willeke F; Cardona S; Mechtersheimer G; Lehnert T; Strauss LG; Herfarth C; Büchler MW
    Ann Surg; 2005 Feb; 241(2):286-94. PubMed ID: 15650639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
    Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
    Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas.
    Collet S; Valable S; Constans JM; Lechapt-Zalcman E; Roussel S; Delcroix N; Abbas A; Ibazizene M; Bernaudin M; Barré L; Derlon JM; Guillamo JS
    Neuroimage Clin; 2015; 8():448-54. PubMed ID: 26106569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.
    Pio BS; Park CK; Pietras R; Hsueh WA; Satyamurthy N; Pegram MD; Czernin J; Phelps ME; Silverman DH
    Mol Imaging Biol; 2006; 8(1):36-42. PubMed ID: 16362149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography.
    Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Hasegawa T
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):683-91. PubMed ID: 16506050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity.
    Jager PL; Plaat BE; de Vries EG; Molenaar WM; Vaalburg W; Piers DA; Hoekstra HJ
    Clin Cancer Res; 2000 Jun; 6(6):2252-9. PubMed ID: 10873075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
    Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
    J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients.
    Rakheja R; Makis W; Skamene S; Nahal A; Brimo F; Azoulay L; Assayag J; Turcotte R; Hickeson M
    AJR Am J Roentgenol; 2012 Jun; 198(6):1409-16. PubMed ID: 22623556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.